By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

Retatrutide (Triple Agonist): An Evidence-Graded Monograph

Direct answer

Retatrutide (Eli Lilly code LY3437943) is an investigational, once-weekly injectable peptide that activates three metabolic receptors at once — GIP, GLP-1, and glucagon — which distinguishes it from GLP-1-only semaglutide and the GIP/GLP-1 dual agonist tirzepatide (Jastreboff et al., NEJM 2023). In Lilly's Phase 2 obesity trial (NEJM 2023, n=338), the 12 mg dose produced a mean 24.2% body-weight reduction at 48 weeks versus 2.1% on placebo (NEJM 2023). The pivotal Phase 3 TRIUMPH-1 trial, reported May 21, 2026 (n=2,339), found a mean 28.3% reduction at 80 weeks on 12 mg (Lilly investor release, May 2026). Adverse events were predominantly gastrointestinal and mostly mild to moderate. As of June 2026, retatrutide is not FDA-approved for any use anywhere in the world, and no approved drug product exists. Material sold online as a "research peptide" is unapproved and labeled "research use only — not for human consumption."

What retatrutide is

Retatrutide is a synthetic peptide therapeutic developed by Eli Lilly under the code LY3437943. Structurally it is an engineered lipopeptide — a peptide backbone carrying non-natural amino acids (such as 2-aminoisobutyric acid and 2-methylleucine) and a C20 fatty-acid side chain that binds serum albumin to extend half-life, enabling once-weekly subcutaneous dosing (Wikipedia: Retatrutide; structural study, PMC11255275). It belongs to the same broad class as the marketed incretin drugs, but it is not one of them: as of June 2026 it remains investigational and unapproved.

A note on scope. Peptevity covers retatrutide because it is the highest-profile investigational peptide in metabolic medicine and the subject of an active gray-market trade — squarely our editorial lane. The already-approved GLP-1 drugs (semaglutide as Ozempic/Wegovy; tirzepatide as Mounjaro/Zepbound) are FDA-approved branded medicines, covered by our sibling resources rather than here. We mention them only to explain what makes retatrutide pharmacologically different. For how we assign the letter grades used below, see our evidence-grading methodology.

Mechanism: a triple agonist, in plain terms (Grade C — human pharmacology, animal mechanism)

The defining feature of retatrutide is that it activates three receptors simultaneously, where the approved drugs hit one or two. Each receptor contributes a different metabolic lever (Jastreboff et al., NEJM 2023; review, PMC12190491):

  • GLP-1 receptor (GLP-1R) — the lever shared with every drug in the class. Activation enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety, reducing food intake.
  • GIP receptor (GIPR) — the lever tirzepatide added. GIP agonism amplifies the insulin response and is thought to improve tolerability and the metabolic effect when combined with GLP-1R action.
  • Glucagon receptor (GCGR) — the new third lever. Glucagon agonism is associated with increased energy expenditure and hepatic fat mobilization, which is the mechanistic rationale offered for retatrutide's larger weight-loss and liver-fat effects.

Here is the honest comparison the marketing usually muddles:

Compound Receptors targeted Approval status (2026)
Semaglutide GLP-1 only (mono-agonist) FDA-approved (branded drugs)
Tirzepatide GIP + GLP-1 (dual agonist) FDA-approved (branded drugs)
Retatrutide GIP + GLP-1 + glucagon (triple agonist) Investigational — not approved

The receptor pharmacology is established in human and laboratory studies; the clinical superiority of adding glucagon is supported by trial weight-loss magnitudes (below) but has not been tested head-to-head against tirzepatide in a published Phase 3 trial as of this review date. The mechanism is real and well-characterized. By itself, though, it is not a guarantee of long-term outcomes — that is what the trials are for, and they are not finished.

The evidence, by claim and phase

Weight loss — Phase 2 — Grade B (single randomized human trial)

Retatrutide's headline reputation comes from a single, well-conducted Phase 2 trial.

  • Phase 2 obesity trial (NEJM 2023). A 48-week, double-blind, placebo-controlled, dose-ranging trial randomized 338 adults with obesity (or overweight with a weight-related condition) and without type 2 diabetes. At 48 weeks, mean body-weight change was −2.1% on placebo, −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg); at the 24-week mark the 12 mg group was already at −17.5% (Jastreboff et al., NEJM 2023;389(6):514–526). These are large effects for a single trial — but it is one Phase 2 study of moderate size, which is why we grade the obesity claim B (limited human evidence) rather than A until the Phase 3 results are peer-reviewed and published in full.

Weight loss — Phase 3 TRIUMPH-1 — Grade B (topline, peer review pending)

The pivotal Phase 3 data arrived in 2026, on a much larger trial.

  • TRIUMPH-1 (announced May 21, 2026). A randomized, placebo-controlled Phase 3 trial in 2,339 adults with obesity (or overweight) without diabetes reported mean weight loss at 80 weeks of 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) — about 70 lb at the top dose. In a 104-week extension subgroup (BMI ≥35, n=532), the 12 mg group reached 30.3% (Lilly investor release, May 2026). We hold this at Grade B rather than A for a specific reason stated in our evidence-grading methodology: as of this review date these are company-reported topline results, not a full peer-reviewed journal publication. The numbers are striking; the standard for an A is independent peer review of the complete dataset.

The broader TRIUMPH program is a suite of Phase 3 trials, not one study. Beyond TRIUMPH-1 (obesity), it includes TRIUMPH-2 (obesity/overweight with type 2 diabetes), TRIUMPH-3 (obesity with established cardiovascular disease), and TRIUMPH-4 (obesity with osteoarthritis of the knee, reported December 2025) (AJMC coverage). Several of these were still reading out through 2026.

Liver fat (MASLD) — Phase 2a — Grade B (single small randomized human trial)

A separate Phase 2a trial tested retatrutide in fatty-liver disease, and the effect on liver fat was even larger than weight loss alone would predict.

  • MASLD Phase 2a (Nature Medicine 2024). In 98 adults with obesity/overweight and metabolic dysfunction-associated steatotic liver disease (≥10% liver fat by MRI-PDFF), mean relative liver-fat reduction at the 24-week primary endpoint was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg) versus +0.3% on placebo, and 86% of the 12 mg group reached normal liver fat (<5%) at 24 weeks versus 0% on placebo (Sanyal et al., Nat Med 2024;30(7):2037–2048; PMC11271400). This is genuine human evidence (Grade B), but it is a small, short, surrogate-endpoint study — it measures liver fat on imaging, not long-term liver disease outcomes — so it should be read as a strong early signal, not a settled clinical result.

What is not yet established

There is no published Phase 3 cardiovascular-outcomes result, no head-to-head Phase 3 versus tirzepatide, and no long-term (multi-year) safety dataset in the peer-reviewed literature as of June 2026. Claims that retatrutide is "the most powerful weight-loss drug ever" are extrapolations from topline trial figures; the molecule is promising and well-studied for an investigational agent, but its full risk–benefit profile is still being assembled.

Safety (Grade B for short-term GI profile; long-term largely unstudied)

Across the trials, the safety story is consistent and dominated by the gut.

  • Gastrointestinal effects predominate. In the Phase 2 trial, "the most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity," and were reduced by lower starting doses (Jastreboff et al., NEJM 2023). TRIUMPH-1 reported the same pattern with quantified rates at 12 mg versus placebo: nausea 42.4% vs 14.8%, diarrhea 32.0% vs 13.5%, constipation 26.1% vs 10.9%, and vomiting 25.3% vs 4.8% (Lilly investor release, May 2026). The MASLD trial likewise reported transient, generally mild-to-moderate GI events as the most frequent (Sanyal et al., Nat Med 2024).
  • Heart-rate increase. The Phase 2 trial noted dose-dependent increases in heart rate that peaked at about 24 weeks and then declined — a signal worth flagging given the glucagon component, and one of the items long-term trials are designed to characterize (Jastreboff et al., NEJM 2023).
  • Long-term safety is not yet established. These are trial-derived data over weeks to a couple of years in monitored participants. There is no multi-year, post-marketing safety record because the drug is not marketed. That is a fundamentally different situation from the gray-market product discussed below.

A separate, larger safety concern attaches to the gray-market material: products sold online as "research" retatrutide are not made under Good Manufacturing Practice, are not batch-tested for identity, potency, or purity, and carry no adverse-event reporting obligation (FDA — Concerns with Unapproved GLP-1 Drugs). Even where the labeled compound is present, the actual content can differ substantially from the label. The clean-room trial safety profile says nothing about an unregulated vial of uncertain origin. Peptevity does not publish dosing or self-administration instructions for any compound; for the broader framing see our note on what "research use only" means.

The standing Regulatory status block above carries the dated summary; this section explains the nuance, because retatrutide sits in a cleaner — and stricter — regulatory position than most peptides we cover.

  • It is not approved anywhere. No regulator has approved retatrutide for any indication. It is investigational; industry coverage anticipated a U.S. regulatory filing around late 2026, with the earliest possible approval well after (Wikipedia: Retatrutide). We treat that timing as secondary-source expectation, not a confirmed fact, and we will date and update this section against FDA primary sources when a filing or approval is confirmed.
  • It cannot be legally compounded. Unlike semaglutide and tirzepatide — which were briefly compoundable while on the FDA drug-shortage list — retatrutide has never had an approved version, so the shortage exemption never applied. The FDA states that compounded retatrutide is not eligible for the 503A or 503B exemptions: it is not the subject of an applicable USP/NF monograph, is not a component of an FDA-approved drug, does not appear on the 503A or 503B bulks lists, and is not used to compound a drug on the shortage list (FDA warning letter, 2025-09-09).
  • The gray-market "research peptide" lane. Because of that, the only material circulating outside trials is sold as a research chemical labeled "research use only — not for human consumption." On September 9, 2025 the FDA issued warning letters to numerous sellers, describing their retatrutide products as "unapproved new drugs and misbranded drugs" introduced into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FDA warning letter, 2025-09-09). The "research use only" label is a legal category for laboratory reagents, not a loophole that makes the product safe or legal to use as a medicine. For the category framing, see what "research use only" means and whether peptides are legal.

Because this lane is moving quickly — a Phase 3 readout, an expected regulatory filing, and active FDA enforcement are all in play — the date matters. We review this page on the same cadence as our living 2026 regulatory tracker; if a filing or approval changes the status, this monograph is updated and the change is logged under our corrections policy.

Honest bottom line

Retatrutide is the rare investigational peptide where the human evidence is the strong part. A well-run Phase 2 trial and a much larger Phase 3 readout both show large mean weight reductions (roughly 24% at 48 weeks in Phase 2; about 28% at 80 weeks in TRIUMPH-1), with a consistent, mostly-mild-to-moderate gastrointestinal side-effect profile and a triple-agonist mechanism that plausibly explains the magnitude. That is genuinely more clinical signal than almost anything else in the gray-market peptide catalog. But — and this is the part the marketing collapses — it is still investigational. It is not FDA-approved anywhere, full Phase 3 peer-reviewed publication and long-term safety data are pending, and it cannot be legally compounded. The "research peptide" sold online is the unapproved drug the FDA has been sending warning letters about, made outside any quality system. Read the gap honestly: promising and unusually well-evidenced for a drug still in trials, and at the same time legally unapproved and unregulated in the form people actually buy.

For neighboring compounds and the framing this page leans on, compare our monographs on the healing peptide BPC-157 and the copper peptide GHK-Cu, see the category overview of peptides for health and longevity, and read why animal versus human peptide evidence is the line that separates a B from a C.

Frequently asked questions

Is retatrutide FDA-approved? No. As of June 2026, retatrutide is not approved by the FDA — or any regulator worldwide — for any use. It is an investigational triple-agonist peptide (Eli Lilly code LY3437943) in the Phase 3 TRIUMPH program, and no approved drug product exists as of this date (NEJM 2023; FDA warning letter, 2025-09-09). The only legitimate access is enrollment in a clinical trial.

How is retatrutide different from semaglutide and tirzepatide? It activates three receptors instead of one or two. Semaglutide is a GLP-1-only agonist; tirzepatide is a GIP/GLP-1 dual agonist; retatrutide adds a third target, the glucagon receptor, making it a GIP/GLP-1/glucagon triple agonist (NEJM 2023; review, PMC12190491). The glucagon component is associated with increased energy expenditure, which is the proposed reason for its larger weight-loss and liver-fat effects in trials.

How much weight did people lose with retatrutide in trials? In the Phase 2 obesity trial (n=338), the 12 mg dose produced a mean 24.2% body-weight reduction at 48 weeks versus 2.1% on placebo (Jastreboff et al., NEJM 2023). In the Phase 3 TRIUMPH-1 trial reported in May 2026 (n=2,339), the 12 mg dose produced a mean 28.3% reduction at 80 weeks, rising to 30.3% in a 104-week extension subgroup with higher baseline BMI (Lilly investor release, May 2026). The Phase 3 figures are company-reported topline results pending full peer-reviewed publication.

What are the main side effects of retatrutide in the trials? Gastrointestinal events dominated and were dose-related and mostly mild to moderate. In TRIUMPH-1 at the 12 mg dose, rates versus placebo were nausea 42.4% vs 14.8%, diarrhea 32.0% vs 13.5%, constipation 26.1% vs 10.9%, and vomiting 25.3% vs 4.8% (Lilly investor release, May 2026). The Phase 2 trial also noted a dose-dependent heart-rate increase that peaked around 24 weeks (NEJM 2023). Long-term safety is not yet established in the published literature.

Is the "retatrutide peptide" sold online the same as Lilly's drug? It is sold as the same molecule, but it is not the same product. Online "research" retatrutide is an unapproved drug made outside Good Manufacturing Practice, not batch-tested for identity, potency, or purity, and labeled "research use only — not for human consumption." The FDA issued warning letters in September 2025 describing such products as unapproved and misbranded drugs (FDA warning letter, 2025-09-09; FDA — Concerns with Unapproved GLP-1 Drugs).

How we graded this page

Every claim above is tied to its strongest primary source and labeled by trial phase and species, per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement.

Primary sources

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Related on Peptevity

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.